Full-Time

Senior Implementation Manager

Phil

Phil

201-500 employees

Digital platform enabling expedited prescription access

Compensation Overview

$130k - $150k/yr

Remote in USA

Remote

Remote in AZ, CA, CO, FL, GA, IA, ID, IL, IN, MA, MI, MO, NC, NH, NJ, NY, OH, OK, OR, PA, SC, TN, TX, UT, VA, WA, WV

Category
Business & Strategy (2)
,
Required Skills
LLM
SQL
REST APIs
Requirements
  • Bachelor’s degree or equivalent experience
  • 10+ years of technology-enabled services implementation experience
  • 5+ years of vendor-side ownership of enterprise implementations
  • 5+ years managing cross-functional and project-specific teams in a matrixed environment
  • Demonstrated ability to translate business objectives into technical architecture and operational execution
  • Strong analytical and problem-solving skills with a data-driven approach to decision making
  • Technical fluency in enterprise integrations including APIs, SFTP, flat file transfers, and SQL
  • Familiarity with AI and LLM applications within technology-enabled service environments
  • Experience designing implementation processes, documentation standards, and scalable delivery frameworks
  • Proven ability to influence stakeholders and negotiate solutions across diverse internal and external constituencies
  • Self-motivated, proactive, and comfortable operating in fast-paced, ambiguous environments
  • Excellent written and verbal communication skills, with the ability to translate technical concepts to non-technical audiences
  • Ability to travel up to 25%
Responsibilities
  • Own full-cycle implementation delivery from kickoff through activation, ensuring alignment between contractual scope, client goals, and technical solution design
  • Lead discovery and current state assessments, translating client objectives into detailed technical specifications and operational protocols
  • Design and document complete program architecture, including configuration standards, business logic, operating rules, and adoption pathways
  • Create and maintain a centralized source of truth outlining solution design, workflows, and reporting structures
  • Drive cross-functional execution across product, engineering, operations, sales, and client success to ensure on-time delivery and operational readiness
  • Monitor and report on implementation health, including status updates, risk tracking, and priority dashboards
  • Serve as a product subject matter expert, understanding PHIL’s platform capabilities, roadmap, integrations, and data workflows
  • Oversee logging and follow-through on technical requests, ensuring tickets are properly grouped, tracked, and aligned to broader initiatives
  • Identify opportunities for process improvement, standardization, and efficiency gains in delivery methodology
  • Influence internal and external stakeholders to resolve complex issues while maintaining scope integrity and project momentum

Phil.us offers PhilRx, a digital health platform that streamlines obtaining prescribed medications for patients and helps providers manage care. It coordinates clinicians, payers, and pharmacies through a national dispense network, real-time HIPAA-compliant data, and workflows for prior authorization and formulary access. It stands out by delivering an integrated medication-access workflow along with consulting services and telemedicine, not just software. Its goal is to improve patient adherence and increase insured prescriptions while earning revenue from platform subscriptions, consulting services, and potential per-prescription economics.

Company Size

201-500

Company Stage

Debt Financing

Total Funding

$158.6M

Headquarters

San Francisco, California

Founded

2015

Simplify Jobs

Simplify's Take

What believers are saying

  • Phil secured $60M from K2 HealthVentures in 2026 to integrate AI and expand reach.
  • Phil grew prescription volumes 10x since 2021 Series D with 150% 2024 revenue growth.
  • Phil partners with Tenpoint, Teva, RedHill for YUVEZZI, Digihaler, Talicia access programs.

What critics are saying

  • CoverMyMeds 90% HCP adoption routes scripts away, eroding Phil's PA edge in 6-12 months.
  • McKesson RelayHealth APIs commoditize formulary negotiation, causing 30% HCP churn in 3-9 months.
  • Express Scripts step therapy blocks YUVEZZI fills, slashing Tenpoint revenue by 50% in 6-12 months.

What makes Phil unique

  • PhilRx automates prior authorizations with 85% success rates via HCP workflow integration.
  • Phil provides real-time HIPAA-compliant script insights and territory dashboards for pharma brands.
  • Phil's 50-state pharmacy network ensures 98% insurance coverage and lowest out-of-pocket costs.

Help us improve and share your feedback! Did you find this helpful?

Your Connections

People at Phil who can refer or advise you

Benefits

Health Insurance

Dental Insurance

Vision Insurance

401(k) Retirement Plan

Remote Work Options

Flexible Work Hours

Growth & Insights and Company News

Headcount

6 month growth

3%

1 year growth

5%

2 year growth

2%
Business Wire
Apr 2nd, 2026
Tenpoint Therapeutics partners with PHIL to launch direct-to-patient cash program for YUVEZZI presbyopia therapy

Tenpoint Therapeutics and PHIL Inc. have launched a direct-to-patient cash programme for YUVEZZI, the first FDA-approved dual-agent prescription eye drop for presbyopia treatment. The programme aims to improve access to the therapy through affordable pricing, home delivery and dedicated support. Presbyopia affects nearly 128 million Americans and approximately 2 billion people globally, with many patients going untreated due to high out-of-pocket costs and limited access. The partnership seeks to reduce these barriers and support long-term treatment adherence. YUVEZZI contains carbachol and brimonidine tartrate ophthalmic solution at 2.75%/0.1% concentration. PHIL operates a healthcare technology platform that connects pharmaceutical manufacturers with patients to provide more convenient and affordable medication access.

PharmiWeb.com
Apr 2nd, 2026
Tenpoint Therapeutics Ltd and PHIL partner to launch YUVEZZI(TM) direct-to-patient cash program to make novel presbyopia therapy more accessible and affordable.

Tenpoint Therapeutics Ltd and PHIL partner to launch YUVEZZI(TM) direct-to-patient cash program to make novel presbyopia therapy more accessible and affordable. SCOTTSDALE, Ariz.-(BUSINESS WIRE)-Tenpoint Therapeutics, a leading ophthalmic manufacturer, and PHIL Inc., an all-in-one digital hub and Direct-to-Patient platform, today announced the launch of a Direct-to-Patient (DTP) cash program for YUVEZZI(TM), the first and only dual-agent prescription eye drop FDA-approved for the treatment of presbyopia. Why Direct-to-Patient Access Matters for Presbyopia Patients Access and adherence remain persistent challenges in ophthalmology, where treatments are often underutilized due to a complex patient journey with high affordability barriers. Presbyopia, an ophthalmic condition that affects nearly 128 million Americans and approximately 2 billion people globally, has traditionally seen patients go untreated due to high out-of-pocket costs and limited therapy access (AOA, 2023). The opportunity to help meaningfully improve access to presbyopia therapy for millions of patients has never been greater. Modernizing the Access Journey for YUVEZZI(TM) Tenpoint and PHIL have partnered to launch an innovative DTP program, delivering YUVEZZI(TM) directly to patients through a seamless access experience with affordable, transparent pricing, home delivery, and dedicated support. This groundbreaking partnership reflects our shared commitment to improving how presbyopia patients receive therapy through reducing access barriers, lowering out-of-pocket costs, and supporting long-term treatment adherence for presbyopia patients. "We are excited to partner with Tenpoint Therapeutics as they launch YUVEZZI(TM)- a meaningful leap forward for presbyopia patients across the country. For the 128 million Americans living with this condition, our direct-to-patient program provides a seamless and accessible path to this innovative therapy. This partnership demonstrates what's possible when patient access is a top priority." - Deepak Thomas, CEO & Founder, PHIL About Tenpoint: Tenpoint Therapeutics Ltd. is an ophthalmic pharmaceutical company focused on the commercialization of YUVEZZI(TM)(carbachol and brimonidine tartrate ophthalmic solution) 2.75%/0.1%, the first and only dual-agent eye drop for the treatment of presbyopia, a condition that affects nearly 128 million people in the U.S. and approximately 2 billion people globally.[1,2] By understanding real-world needs and partnering with eye care professionals, Tenpoint is working to bring innovation to the aging eye. For more information, visit tenpointtherapeutics.com. About PHIL Inc.: PHIL is a healthcare technology platform that partners with pharmaceutical manufacturers to empower patients with more convenient and affordable access to their prescribed medications. Through PHIL's digital hub and direct-to-patient platform, PHIL supports access, affordability, and adherence at scale. For more information, visit phil.us. [1] American Optometric Association Health Policy Institute. New Approaches to Presbyopia. 2023. Accessed November 5, 2025. Available at https://www.aoa.org/AOA/Documents/Advocacy/HPI/presbyopia%20brief%20HPI%20Final.pdf. [2] Fricke TR, Tahhan N, Resnikoff S, et al. Global Prevalence of presbyopia and vision impairment from uncorrected presbyopia: systematic review, meta-analysis and modelling. Ophthalmology. 2018;125(10):1492-9. Editor details. * Company: * Businesswire Last Updated: 02-Apr-2026

FinSMEs
Jul 9th, 2025
Phil Receives $60M Growth Capital Facility from K2 HealthVentures

Phil receives $60M growth capital facility from K2 HealthVentures.

Health Technology Insights
Jul 8th, 2025
Phil Secures $60 Million Growth Capital from K2 HealthVentures to Boost AI Integration

Phil, a leading software-driven pharmaceutical commercialization platform, announced a $60 million growth debt financing from K2 HealthVentures, a healthcare and life sciences-focused investment firm.

PR Newswire
Jul 8th, 2025
Phil Secures $60M for AI Integration

Phil, a pharmaceutical commercialization platform, secured a $60 million growth capital facility from K2 HealthVentures to enhance AI integration and expand customer reach. Since its Series D in 2021, Phil has increased prescription volumes over 10x and achieved 150% year-over-year net revenue growth in 2024. The funding will help Phil improve patient care and access, leveraging its software-driven model to overcome traditional barriers in the pharmaceutical industry.